Coronavirus: Oxford-AstraZeneca vaccine 'behaves as desired', analysis finds

Henrietta Brewer
October 23, 2020

More than 8 million Americans have been infected with the novel coronavirus and more than 200,000 have died.

While the question hasn't received much attention among the general public, it's one that worries health experts and pharmaceutical manufacturers.

Half the volunteers in the final-stage clinical trial - a double-blind, randomized, controlled study - receive a placebo, IDOR said.

Over 10,000 volunteers have been recruited for the trial, with 8000 already given the first dose, a spokesperson for the Federal University of Sao Paulo, which is helping coordinate the trial, said.

The aim is to observe over the course of months how many people in each group naturally contract the virus and fall ill from Covid-19. "All significant medical incidents, whether participants are in the control group or the COVID-19 vaccine group, are independently reviewed".

But for a permanent authorization, the FDA requires a longer period of study - generally six months.

The possible side effects of the vaccine could include fever, pain at the site of the intramuscular injection and malaise. Bloomberg News, citing an anonymous source, also reports that the participant received a placebo. It is up to the companies to choose the states where they want to conduct the trials and hence, they have asked us, he added.

Anvisa did not immediately clarify whether the volunteer was taking the vaccine or the placebo, and the situation is still under review.

Zaks confirmed to the London-based medical journal that Moderna's trial will not show prevention of hospitalization because the size and duration of the trial would need to be vastly increased to collect the necessary data. The authorities have not revealed any further information, but indicated that the trial would continue.

But the dilemma is real for the majority.

The scientist explained that after negotiations with the government on the transition to the clinical trial phase, documentation on the development of the vaccine will be transferred to the World Health Organization (WHO).

Dr David Matthews, of Bristol's School of Cellular and Molecular Medicine, who led the research, said: "This is an important study as we are able to confirm that the genetic instructions underpinning this vaccine, which is being developed as fast as safely possible, are correctly followed when they get into a human cell". That committee suggested the trial should continue, Anvisa said in a statement.

Other reports by iNewsToday